Close

Mizuho Securities Downgrades Eagle Pharmaceuticals (EGRX) to Neutral; Stock to Plateau Post-Analyst Day

Go back to Mizuho Securities Downgrades Eagle Pharmaceuticals (EGRX) to Neutral; Stock to Plateau Post-Analyst Day

Eagle Pharmaceuticals (EGRX): Analyst Day Takeaway - RBC

November 14, 2016 6:56 AM EST

RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on shares of Eagle Pharmaceuticals (NASDAQ: EGRX) after the analyst day and is confident in the BENDEKA base and encouraged on the potential for value creation.

Pipeline was the focus at the analyst... More